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Mitsubishi UFJ Research and Consulting (MURC) is a comprehensive think 
tank/consulting arm of the Mitsubishi UFJ Financial Group (the MUFG Group, a 
universal banking group that represents Japan) and based in the three major cities in 
Japan. MURC established the “Center on Global Health Architecture” in 2017 and 
organized a public private collaborative action-oriented research meeting on global 
health issues. We aim to promote relationships among stakeholders, “break down 
silos,” and take an interdisciplinary approach to create new and innovative projects. 
 
Abstract 
Our prioritized areas are i) re-mapping private companies that make a contribution to 
global health to create a new evaluation tool to promote investment from the private 
sector; ii) advocating the reform of UN procurement and public procurement 
mechanisms in emerging countries to Japanese and other private companies, and; iii) 
promoting regulatory harmonization on medical devices/equipment beyond borders 
and building capacity for regulators and policymakers in low- and middle-income 
countries (LMICs). Of these focus areas, we are commencing specific projects to 
explore the first two items. In this paper, we share our proposed solution to global 











Figure 1: The three ideas which underpin this paper and its proposed solutions. This 
article will focus mostly on the two highlighted in red.  
Source: Author’s own.  
Re-map private companies which contribute to global health and create a new 
evaluation tool to promote investment from the private sector 
Despite advances in global health, including improved access to medical 
technologies such as medicines, vaccines, medical devices and equipment, and AI-
driven systems, the world is still facing anxiety and uncertainty over future pandemics 
and the threat of new infectious diseases1. In recent years, new types of global health 
issues have emerged. For example, antimicrobial resistance (AMR) is attracting notable 
attention. Because of AMR, some standard treatments are becoming ineffective, which 
means that infections persist and may spread to those previously unaffected. The 
World Health Organization (WHO) estimates that antibiotic treatments add an 
average of 20 years to all of our lives, but in the 80 years since the discovery of 
penicillin, the overuse of antibiotics has put pressure on bacteria to evolve resistance. 
This has led to the emergence of untreatable superbugs that threaten the basis of 
modern medicine.  
Malnutrition also remains a major issue and affects health in developing 
countries. Furthermore, we must now also confront the rampant increase in various 
non-communicable diseases (NCDs) such as diabetes and obesity. These NCDs are 
currently an issue in both developed and developing countries. In some nations where 
the population is aging, brain-related diseases such as Alzheimer’s disease and 
dementia are becoming serious issues. All these afflictions are intertwined with each 
other in complex ways. 
When looking at the amount of investment flowing into global health, can we 
say that it is sufficient? The purpose of this report is not to show accurately whether 
it is or is not. If we focus on how to secure a stable budget for international health, 
information can be gleaned from several global health metrics. One in-depth article 
collected budget data on the primary agencies and organizations that provided 
financial assistance to LMICs for global health issues from 1990 to 2014. During this 
period, 458 billion USD was distributed through major channels for health funding 
 




Improve/Solve the Global Health issues more effectively and efficiently
1. Re-map of & Engagement 
from Industrial sector
2. Advocacy on Reform of 
UN/Public Procurement
3. Promotion on Regulatory 
Harmonization
◼ promote regulatory harmonization on medical 
devices/equipment beyond borders and capacity 
building for regulators and policy makers in LMICs.
◼ advocate the reform of UN procurement and public 
procurement mechanism in emerging countries to 
Japanese private companies and some others.
◼ re-map private companies which make a contribution to 
global health and create a new evaluation tool to 
promote the investment from private sector.
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from donor countries to LMICs. Annual disbursements increased substantially from 
$6.9 billion in 1990 to $35.9 billion in 2014 2.  
Following the transition to a new administration in the United States, it is likely 
that public funding for global health will face new difficulties. However, the UN 
adopted its Sustainable Development Goals (SDGs) in 2015, and the new international 
framework for global development emphasizes the importance of the private sector in 
driving solutions, including for global health issues. Now is the time for us to think 
about how we can stabilize or increase global funding for global health by inducing 
greater commitment from the private sector.  
 
Figure 2: Development assistance for global health (2014 US dollars) 
Source: Joseph L. Dieleman et al., “Sources and Focus of Health Development 
Assistance, 1990-2014”, JAMA Vol.313, no. 23 (June 2015):2362 
 
In terms of investment in the private sector, increasing attention is being paid 
worldwide to environmental, social, and governance (ESG) investment. ESG 
investment criteria are a set of standards for a company’s operations which socially 
conscious investors use to screen investments. The “E” in “ESG” is concerned with 
how a company performs as a steward of the natural environment; “S” examines how 
a company manages relationships with its employees, suppliers, customers, and 
communities; and “G” deals with a company’s leadership and the adequacy of its 
management and administration, including relationship-building with various 
stakeholders.  
In 2016, $22.89 trillion was invested based on perspectives of ESG, an increase 
of 25% compared to 2014. In 2016, global ESG investment accounted for 26% of all 
outstanding assets under management3. There are several possible reasons for the 
 
2 Joseph L. Dieleman et al., “Sources and Focus of Health Development Assistance, 1990-
2014”, JAMA Vol.313, no. 23 (June 2015):2362 
3 Global Sustainable Investment Alliance, “Global Sustainability Investment Review 2016”, 




increase in ESG investment. First, the advent of Principles for Responsible Investment 
(PRI) in 2006 is having a meaningful impact on decision-making and is supported by 
an international network of investors who have pledged to incorporate ESG into their 
investment and ownership (asset management) decisions4. Second, ESG indices 
themselves have become diversified and more detailed. Therefore, it is becoming 
easier for investors to evaluate companies based on ESG or similar criteria. Third, 
research has confirmed the positive correlation between ESG and corporate financial 
performance5. 
 
Figure 3: Growth of ESG Assets by Region 2014–2016 
Source: Global Sustainable Investment Alliance, “Global Sustainability Investment 




The social aspect of the ESG framework (“S”) has a high “affinity” for global 
health issues and their associated businesses and activities, and it has the potential to 
induce investment from private companies. Some corporations might have anxiety 
about rising costs and being negatively evaluated under such a framework. However, 
we believe that ESG will generate opportunities for companies to enhance their value.  
ESG rating agencies and their frameworks for private companies, such as the 
Dow Jones Sustainability Index and FTSE4Good, can be useful tools. For global 
health-related industries, the Access to Medicine Index is one of the most well-known 
ESG-related frameworks. It is managed by the Access to Medicine Foundation based 
in Amsterdam. Another example is the Access to Nutrition Index. These indices are 
 
4 “PRI: Home,” The PRI, accessed March 19, 2018, https://www.unpri.org/ 
5 Gunnar Friede, Timo Busch and Alexander Bassen, “ESG and financial performance: 
aggregated evidence from more than 2000 empirical studies”, Journal of Sustainable Finance 
& Investment. Vol.5, no. 4 (2015):225 
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categorized as human rights-focused frameworks6. According to a survey by 
GlobeScan and SustainAbility, the Access to Medicine Index was ranked one of the 
most credible indices by respondents7. 
 
Figure 4: Ranking of experts’ familiarity with ESG-related indices 
Source: GlobalScan and SustainAbility, “The 2013 Ratings Survey: Polling the 
Experts.” 
 
The Access to Medicine Index is a framework mainly for the pharmaceutical 
industry, and the Access to Nutrition Index is generally used by the food and beverage 
industry. However, the manufacturers that make contributions to global health issues 
are diverse. 
Most public-private collaborative communities for global health issues have 
been organized by the pharmaceutical industry and/or the food and beverage industry. 
 
6 Casey O’Connor and Sarah Labowitz, “Putting the ‘S’ in ESG; Measuring Human Rights 
Performance for Investors”, PUTTING THE “S” IN ESG, (2017):11, 
https://static1.squarespace.com/static/547df270e4b0ba184dfc490e/t/58cad912e58c627418
0b58b6/1489688854754/Metrics-Report-final-1.pdf 
7 GlobalScan and SustainAbility, “The 2013 Ratings Survey: Polling the Experts”, A 





Their main purpose is generally to discuss innovative social mechanisms to promote 
the research and development of specific products geared particularly for LMICs, and 
to subsidize the purchase of such products.  
However, we have come to recognize that it is necessary to include the 
participation of the diverse industries which have the potential to contribute to global 
health issues. In the last 5-10 years, more attention has been paid to the importance of 
diagnostic industries. Recently, startups related to supply chain management and cold 
chains with innovative digital technologies are beginning to work with international 
organizations in this field. Current indices, however, do not properly grasp a holistic 
view of who is actually working and what kind of products or technologies have 
potential in the field. Our proposal would “re-map” all those private companies which 
contribute to global health. 
If we re-map the contributors working on global health issues and establish 
another index for related industries, estimates of global health investment also shift. 
For example, diagnostic devices are indispensable at the first stages of health 
interventions. To monitor and control diseases, important roles in global health are 
played by information and communication devices, the internet of things (ICT/IoT) 
and, more recently, artificial intelligence (AI). Personal protective equipment (PPE) 
has long been provided to promote patient safety as well as to protect medical workers.  
Currently, there is no direct framework for evaluating these varied industries 
according to ESG, especially from the perspective of “S”. As previously mentioned, 
we face a wide variety of issues in global health, ranging from infectious diseases to 
NCDs. These growing issues are matters of international concern. When we consider 
how to secure diverse investment to resolve or mitigate these complex problems, there 
is an urgent need to review and map all of the private sector industries and companies 
contributing to global health. We call this approach “corporate taxonomy.” Under this 
type of corporate taxonomy, multiple stakeholders who are willing to work for global 
health internationally should collaborate to establish several new indices for ESG. The 
purpose should not be just to measure it, but also to have the index disseminated to 
and utilized by stakeholders such as investors, asset managers, shareholders, NGOs, 
and companies themselves. Of course, this is not the only approach that could 
encourage more engagement from private sector on global health issues; however, a 
holistic new framework would encompass many new industries and introduce new 
interest in global health investment. 
It is important to properly understand the advantages and disadvantages of a 
new index to promote more investment from private industries. Positive aspects 
include promoting constructive competition between manufacturers in the same 
industry to enhance the R&D investment and contributions to access and delivery 
issues. The manufacturers can compare their corporate performance more objectively 
in the industry, learn their positioning based on the framework, and utilize it to 
restructure their strategies for international contribution. This could also send a 
message to their stakeholders. There may be negative aspects, too. In some cases, the 
indicators of the index might mislead the industry. While the framework is more 
holistic, it cannot encompass every single indicator. For example, if the organizers of 
the index did decide not to focus on certain specific products or technologies and the 
indicators were affected by such a decision, that might encourage unmet needs in 
global health issues by ignoring some spaces of potential innovation.  
Our proposal is to create a new, more holistic index which includes diverse 
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industries such as the diagnostics field and products like novel digital technologies. 
 
Figure 5: Consciousness of problems on private engagement with global health and 
ESG index 
Source: Author’s own.  
 
Figure 6: Mapping global health and its solutions: “corporate taxonomy” 






< Examples of existing Indices >
◼ The Access to Medicine Index is a ranking system published biennially 
since 2008 by the Access to Medicine Foundation.
◼ The foundation is funded by the Bill & Melinda Gates Foundation 
(BMGF), the UK Department for International Development (DFID) and 
the Dutch Ministry of Foreign Affairs.
◼ It ranks the world’s 20 largest pharma companies biennially
◼ The evaluation framework is composed of the ability to make their 
pharmaceutical drugs more available, affordable, accessible and 
acceptable in LMICs.
◼ The purpose is to stimulate pharma industry to improve access to 
health in developing countries by sharing the info of the peers, and to 
encourage the stakeholders to improve the situation.
◼ The Access to Nutrition Index was founded in 2009.
◼ The methodology was developed by GAIN (Global Alliance for 
Improved Nutrition), and is jointly funded by GAIN, BMGF and the 
Wellcome Trust.
◼ The purpose of the index is to improve the access of consumers to 
more nutritious products, and make a contribution to address the 
serious global problems such as undernutrition and obesity.
◼ That  will allow food/beverage enterprises to benchmark their 
performance on nutrition by sharing the information of their peers.
◼ It will also play a role as a platform to share the useful information and 
promote better decision making by the stakeholders.
“for Pharma industries”Access to Medicine Index “for Food/Beverage industries”Access to Nutrition Index
From 1990-2014, G/H assistance 
from public sectors increased, 
but instable
The Adoption of SDGs encourages
more engagement 
from private sectors
Under the concept of ESGs,
Private sectors need to meet 
proactively with social investment
With new indices to evaluate corporate performances, extract more private investment for global health
Start with re-mapping of contributors to G/H, share the information and  decide the target of next indices
◼ Corporate Taxonomy: The Center on Global Health Architecture, MURC analyzes the complexity of the global health issues as the
following matrixes.
⚫ Regions and issues: categorized the global health issues and scored its seriousness in the regional level by the statistics from
international institutions
⚫ Issues and solutions: mapped the issues analyzed above and possible solutions
◼ The Center is currently preparing the mapping of solutions and its providing enterprises
Issue
HIV/AIDS TB Malaria Hepatitis NTDs AMR
(Re)emerging
I/D




Undernutirition Anemia Obesity Infertility STDｓ Maternal death Infant death Vascular Degenerative Smoking Drug Alcohol Depression Mental illness PTSD
Region Africa 1.22 254 ・・・ ・・・ ・・・ ・・・ ・・・ 17.2 59.3 ・・・ ・・・ ・・・ 542 52.3 ・・・ ・・・ 9.8 ・・・ 6.3 11.96 ・・・ ・・・
America 0.16 27 ・・・ ・・・ ・・・ ・・・ ・・・ 1.6 22.7 ・・・ ・・・ ・・・ 52 12.1 ・・・ ・・・ 16.9 ・・・ 8 9.25 ・・・ ・・・
Southeast Asia 0.08 240 ・・・ ・・・ ・・・ ・・・ ・・・ 26.2 51.4 ・・・ ・・・ ・・・ 164 31.5 ・・・ ・・・ 16.9 ・・・ 4.5 13.4 ・・・ ・・・
Europe 0.18 32 ・・・ ・・・ ・・・ ・・・ ・・・ - 22 ・・・ ・・・ ・・・ 16 8.3 ・・・ ・・・ 29.4 ・・・ 9.8 12.85 ・・・ ・・・
Eastern Mediteranean 0.06 114 ・・・ ・・・ ・・・ ・・・ ・・・ 12.8 45.3 ・・・ ・・・ ・・・ 166 40.6 ・・・ ・・・ 18.1 ・・・ 0.6 4.3 ・・・ ・・・































・・・ Health system Surveilance ・・・
Issue HIV/AIDS 〇 〇 〇 △ △ △ 〇
TB △ 〇 〇 △ △ 〇
Malaria 〇 △ △ 〇
Hepatitis 〇 〇 △ △ △ 〇
NTDs △ 〇 〇 △ △ 〇
AMR 〇 〇 △ △ 〇
(Re)emerging I/D 〇 △ △ 〇
Heart disease 〇 〇 △ △
Cancer 〇 〇 〇 △ △
Diabetes 〇 △ △


































Seriousness of the issue in regional level based on the statistics
Mark whether the solution is effective for each issue
< Issues and solutions >
< Regions and issues >
58 Consilience 
 
Figure 7: Mapping of regions and issues 
Source: Author’s own. 
 
Figure 8: Mapping of issues and solutions, and future development of new index 
Source: Author’s own. 
 
Finally, we would like to highlight three essential points so that the new index 
can be broadly recognized and used. First, the index framework should be established 
by several players, including specifically a human rights-focused agency and a 
corporate rating agency focused on financial performance alongside different types of 
organizations that would bring together their different skillsets to create the index. 
Secondly, the framework should be operated objectively, with the index itself managed 
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HIV/AIDS － － 〇 － ◎ － ◎ 〇 ◎ 〇
TB － ◎ 〇 ◎ ◎ ◎ － 〇 ◎ 〇
Heart 
diseases
◎ － － ◎ ◎ 〇1 〇1 〇 ◎ －
Cancer
－ － － ◎ ◎ － － 〇 〇 〇
Under-
nutrition
－ － － ◎ ◎ － － 〇 〇 〇
Anemia
－ － ◎ － － － － 〇 〇 －
〇
－ ◎

















－ － － － 〇 〇 －
Notes: 1. we categorized antibiotics and antivirals as an indirect solution in the sense of stopping overuse and misuse of 
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separately from the commercial base. Finally, these indices typically target large, 
multinational conglomerates which constantly seek external funding and large 
amounts of investment. However, it is more important for this proposed framework 
to focus on new technologies and businesses operated by small and medium-sized 
corporations all over the world. While there may be some negative impact from 
increasing the available number of indices, it is more important to pursue ways to 
improve global health by establishing new tools. 
 
To encourage more engagement from private industries in global health, such 
an index for new industries created after re-mapping contributors would be 
indispensable. It is important to provide adequate supplies and to install relevant 
products and services into LMICs. While valuable, the index approach is not the only 
way to encourage private investment. There are other channels to consider. For 
example, if we can promote the harmonization of regulations regarding medical- and 
healthcare-related products and services among different countries, private 
corporations could enter more markets. Even during the R&D phase of new 
technologies, current international cooperation is insufficient for clinical trials. 
Encouraging public-private collaborative projects beyond borders could accelerate 
global health research by private corporations. Key to this challenge, the recent reform 
of UN procurement and public procurement mechanisms in emerging countries has 
huge potential to encourage private industries to invest in the global health field. After 
this reform, countries observe more and more private corporations joining its public 
tender as suppliers; Japanese companies are one example of this trend. Because of this 
contribution, the access and delivery of services and technologies is improving for 
some cancer patients in these countries. This kind of social system reform leads to 
behavioral change in private corporations and could also make headway regarding the 
“S” of the ESG framework, as discussed below. 
 
Advocate for the reform of UN procurement and public procurement 
mechanisms in emerging countries 
 
The World Bank Group (WB) introduced a new procurement framework and 
regulations called the “New Procurement Framework” in 20158. Although 
implementation of the new scheme began in July 2016, a couple of years will be 
necessary before it covers the entire range of procurement-related programs of the 
WB.  
The most significant change in the New Procurement Framework is the shift 
from seeking the “lowest evaluated compliant bid” to seeking the bid that “provides 
the best overall value for the money,” which allows the WB to balance quality, cost, 
and other factors when selecting suppliers. 
By transitioning to the new framework, the WB is expected to play a more 
active role in contract management of procurements to pursue greater overall value, 
 
8 “The World Bank: New Procurement Framework and Regulations for Projects 





even though this strategy requires it to account for additional risk factors in order to 
ensure the best possible outcomes. However, focusing on greater value in 
procurements can allow the WB to make a better contribution towards its 
development goals. 
The most important characteristic of the new system is its emphasis on value 
for money (VfM). This change will influence how global procurement throughout the 
WB is conducted. The attention to the VfM principle will also result in changes to 
standard bidding document forms, including the request for bid (RFB) and request for 
proposal (RFP) forms. The RFP form now allows greater flexibility when responding 
to the “specification” and “design” options. 
Other significant changes have been made to the evaluation criteria. The WB 
is adopting a more comprehensive framework for evaluation that incorporates mid- 
and long-term maintenance costs, safety considerations, environmental and social 
considerations, and various qualitative factors. Although such evaluation criteria have 
commonly been used in national Private Financial Initiative programs, the new WB 
procurement framework also applies these concepts to the international development 
field. Thus, greater attention must be paid to balancing lifecycle impacts of programs 
and their multidimensional cost. 
To give a direct comparison, under the previous RFB system, “cost-related” 
criteria accounted for 70% of the bid evaluation and “quality” criteria for the remaining 
30%, whereas under the new scheme “quality” accounts for up to 50% of the 
evaluation. This change will apply to all types of procurements, from goods and 
services to consultancies. Given that the annual amount of the WB’s procurement is 
about 64 billion USD, the new scheme will have a huge impact on affected businesses 
and suppliers9. 
The annual procurement volume of the United Nations (UN) and its funds, 
programs, specialized agencies, and other divisions totals about 20 billion USD, half 
of which is for the procurement of goods. In the coming years, the total UN budget 
is likely to decline. However, the volume of the UN-related procurement is still huge, 
existing as “a global marketplace.” 
The WB and the UN, to a significant extent, have a shared agenda and have 
many collaborative projects. The WB has some influence on the UN’s agenda setting, 
policy making, and on-site implementation. When the two (or more) organizations 
implement a joint procurement, the procurement policy of one organization could be 
used by other collaborative partners in similar situations. Therefore, the new scheme 
of the WB could affect the procurement policies of other international agencies, 
especially as the Sustainable Development Goals (SDGs) become more widespread.  
We expect that the new WB scheme will create a good opportunity to support 
international agencies, governmental policymakers, and multinational private 
corporations and to help reconsider the meaning of “sustainable development” and 
ways that “sustainable procurement” can be pursued as part of the SDGs. One 
 
9 United Nations Office for Project Services, “Major purchase orders and 
contracts by UN organization,” 2015 Annual Statistical Report on United Nations 
Procurement, 2016, 
https://www.unops.org/SiteCollectionDocuments/ASR/ASR_2015_Major_purcha
se_orders_and_contracts.pdf, accessed on July 31st, 2017 
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example of this is found in Japan. 
Since 2009, the Government of Japan has renewed its strategy on public–
private partnerships for international development and begun accepting proposals 
from private companies, organizations, and universities that plan to enter into the 
market in developing countries. These private entities intend to pursue not only profit, 
but also social objectives to contribute to international development and cooperation. 
The Ministry of Foreign Affairs, the Japan International Cooperation Agency (JICA) 
and the Ministry of Economy, Trade, and Industry are working collaboratively to 
implement and manage public-private partnerships. This new scheme was originally 
called the “Preparatory Survey for Base of Pyramid (BoP) Business Promotion” and 
was renamed the “Feasibility Survey for SDGs Business Promotion” in 2017. It has 
already adopted more than 100 proposals by private entities, ranging from 
infrastructure-related plans to projects with social objectives. Many intend to improve 
development problems and introduce innovative solutions in developing countries for 
issues such as the prevention of hospital-acquired infections, vector control, the 
improvement of malnutrition, and the introduction of renewable energy sources. This 
governmental program provides financial assistance for feasibility studies. 
Figure 9: Preparatory survey for BoP business promotion: examples of adopted 
projects 
Source: Japan International Cooperation Agency, “Preparatory Survey for BOP 
business promotion – List of Projects,” 2017, 
https://www.jica.go.jp/english/news/press/ 2017/8/1, accessed July 31st, 2017 
 
Several private entities that have received support are providing their own 
products to contribute to solving and improving development issues in target 
countries. The sales models of these businesses show that one of their targets is public 
procurement, including by the UN and its concerned parties.  
Japanese products tend to be “high quality but high cost,” and this has long 
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been a characteristic of goods “made in Japan.” Recently, some Japanese 
manufacturers have been trying to cooperate with local and foreign companies to 
create a new type of product that is “made with Japan.” However, they are just in the 
beginning stages of these efforts. It is important to note, as previously mentioned, that 
the approval of the new procurement framework by the WB will potentially increase 
the use of the VfM concept in the procurement systems of international agencies. 
These practices will spread to current emerging and developing countries. Because of 
this, more “high cost but high quality” goods and services will be purchased and will 
make an even greater contribution to “Sustainable Procurement for Sustainable 
Development” than ever before. Of course, businesses must continuously push to 
control costs without reducing quality. 
A new initiative on “Open Contracting” in emerging countries is moving 
forward. “Open Contracting” is the reform of public procurement mechanisms to 
improve transparency and accountability for sustainable development. Public 
procurement system reform has been conducted in Ukraine for the last 3 years. 
Additionally, most of the countries in the Southern Common Market (MERCOSUR) 
are joining the initiative. Behind the discussion on “Open Contracting,” there is a 
motivation to encourage local authorities to be more accountable. This includes 
including clarifying their attitude towards anti-corruption and promoting e-
procurement to achieve higher efficiency and to improve the effectiveness of their 
system.  
In 2013, the price for anticancer drugs in Ukraine was 40% higher than market 
price. Only a few suppliers were operating. The Minister of Health made a 
fundamental reform on medicine supplies to assign UNDP, UNICEF, and Crown 
Agents as the procurement agencies for anti-HIV drugs, anti-TB drugs, and anticancer 
drugs to promote the reform in 2016. By sticking the knife into vested interests, 38% 
of the procurement cost were reduced from 2015. Furthermore, the number of 
suppliers increased from 2-3 to 29. They improved the quality of goods and held strict 
observance of delivery times. With this political reform, new foreign companies, 
including Japanese companies, are also joining the public tender in Ukraine. In 2017, 
due to the savings achieved, Ukraine was able to procure coronary stents for all 
patients for the first time ever. Before then, only 50% of the patients had received 
treatment. The Ukrainian Ministry of Health is internally considering a new division 
to manage a comprehensive system for public procurement, to be installed in 2020. 
 
Figure 10: Editorial by the Lancet on Ukrainian Reform on Public Procurement 
Source: “Measles, war, and health-care reforms in Ukraine”, The Lancet Vol. 392 
(September 2018). 
 
◼ “The health-care reforms, led by US-born Uluana Suprun, profiled in this week’s issue, include the introduction of an internal 
market structure, a shift of care from a hospital to a community-based service, and the elimination of corruption and bribery.”
◼ “Patients currently make up the 45.6% shortfall of the 7.6% of GDP spent on health with out-of-pocket and informal payments.”
◼ “Bed numbers and patients’ average length of hospital stay will be reduced. Western-backed support for the reforms comes from 
the UN Development Programme, UNICEF, and the UK procurement agency, Crown Agents, now responsible for purchasing 5.9 
billion Ukrainian hryvnia (about US$ 212 million) of medicines for the country.”
◼ “The service— developed from the Soviet Semashko system—is seen by many as inefficient and inequitable; nevertheless some 
politicians and doctors remain opposed to the changes.”
◼ “More generally, the World Bank has also endorsed Ukraine’s efforts to achieve lasting economic recovery.”
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Conclusion 
For years, the established communities for global health issues have been those 
organized by the pharmaceutical and the food and beverage industries. Their main 
objectives were to discuss innovative social mechanisms, promote R&D of products 
mainly for LMICs, and subsidize those purchases. We have, however, come to 
recognize that it is necessary to promote the participation of more diverse industries 
which have great potential to contribute to global health issues. In the last decade, 
diagnostic industries have had an increasing presence in the field. For the last few 
years, industries focusing on supply chain management and cold chains have especially 
been adopting novel digital technologies such as AI and machine learning. However, 
we must reflect on what more we can do to get different players involved with global 
health. It is one of the most complex issues internationally, and yet there is not a 
holistic and adequate understanding who is actually working and what kind of products 
and technologies have potential. Thus, we need to re-map the contributors to global 
health issues and solutions.  
Based on this re-mapping, an index for new industries to evaluate and visualize 
the performance of corporations would be indispensable so that we can induce more 
engagement from private companies in global health. Such an index couples well with 
the recent trend of ESG investment to attract more interest from social investors, 
which can lead to more engagement from new industries. There is a particularly high 
expectation that creating a new index would make a huge impact for diagnostic 
industries and new digital technology-related industries. However, the index approach 
is not the only way to encourage more investment from private industries. It is also 
important to reform certain established social systems in the world. The reform of UN 
procurement and public procurement mechanisms in emerging countries could have 
a huge potential to encourage engagement by private industries on global health issues. 
That, too, could also contribute to the “S” of the ESG framework.  
 
Figure 11: Basic framework for sustainable development in global health 
Source: Author’s own. 
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Furthermore, there are other intervening opportunities based on social 
infrastructure to enhance the provision of products/services by encouraging 
commitments from private industries. Continuous R&D investment in innovative 
products is always really indispensable. To innovate and to drastically change the 
social situation surrounding global health issues, we must develop a new type of 
solution. For that, we need to promote R&D investment and support R&D within 
the private sector. IN some industries, several established Product Development 
Partnerships (PDPs) collaboratively work together with private companies to invent 
new products, especially medicines and diagnostic devices. These PDPs have great 
capacity to work in other industries, too. In some cases, an accelerator program to 
seek ideas for new technology-based products and to support the scaling-up of such 
new disruptive solutions is necessary. Clinical trial is also key. To support R&D, 
establishing networks with and collaborative environments in local institutions in 
emerging and developing countries for clinical trial is also indispensable. 
International NGOs and local NGOs could be additional strong partners for clinical 
trials. Thus, private companies should have a deeper understanding of their culture 
and way of thinking. A multiple stakeholder approach may be more effective to 
enhance collaboration based on better mutual understandings.  
Similarly, regulatory harmonization has garnered more and more attention in 
recent years. Current regulatory affairs also pose a challenge to putting products and 
solutions into the field. Recently, the coordination of regulations among countries 
and regions is being implemented. To provide solutions more efficiently, regulatory 
harmonization is sine qua non. What ultimately matters is to take regulatory 
harmonization one step further by investing in capacity building for regulators and 
policymakers in LMICs at the same time.  
Unfortunately, there is still a severe problem regarding product delivery. 
“Last-mile” interventions should be prioritized as well to reach underserved 
populations and to minimize negative factors affecting sustainability. Japanese 
players have been establishing distribution systems in ASEAN countries to some 
extent; however, there has not been enough done in African countries. In such areas, 
we need to work collaboratively with global cooperation. Alongside last-mile 
interventions, there are also challenges in supply chain management and even 
stockpiling, in some cases. Stockpiling strategies, such as supply division storage by 
UNICEF for development and emergency situations, and the international depot by 
The United Nations Humanitarian Response Depot (UNHRD) for emergency relief, 
enable prompt action when emergency demands need to be met. Although the Japan 
Disaster Relief Team uses UNHRD Depot for emergency cases, the Japanese private 
sector does not fully understand its existence and importance. For both 
developmental and emergency purposes, a more efficient and effective system for 
supply management based on a public-private collaborative approach will be required 
to increase efficiency and effectiveness.  
Lastly, maintenance of installed products and the introduction of leasing 
contracts should be considered. As products and services become more high-tech, 
maintenance in developing countries becomes more important. To pursue 
sustainable development, we should not accept a culture in which products are 
disposable and thrown away while similar goods are repurchased. It is vital to 
determine how to provide maintenance through the private sector and how to foster 
the use of local agencies. It would be worth considering contracting to provide such 
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products. The use of leasing will become more common as we seek to reduce 
procurement costs and to promote adequate maintenance. For example, leasing 
systems for automobiles, agricultural machines, construction machines, and some 
back-office products such as photocopiers could be applied to the UN procurement 
system. 
While a new, holistic valuation framework based on remapping of global 
health contributors and procurement reforms can encourage different companies to 
invest in  complex international issues, there are still many other aspects that we 
should consider to inspire more and more private corporations to make a 
contribution to global health issues. Some of them would also lead to broader stake 
in SDGs. To materialize these concepts, we believe that we need to take action with 
the evidence and suggestions provided in this paper. 
 
